Recent News

• 06.30.2025 - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
• 06.25.2025 - Addex Shareholders Approve All Resolutions at Annual General Meeting
• 06.19.2025 - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
• 06.18.2025 - Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
• 06.06.2025 - Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
• 06.05.2025 - Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
• 06.03.2025 - Addex Convenes Annual General Meeting 2025
• 05.12.2025 - Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Recent Filings

• 06.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.30.2025 - EX-99.1 EX-99.1
• 06.25.2025 - EX-99.1 EX-99.1
• 06.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.23.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.20.2025 - EX-99.1 EX-99.1
• 06.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.06.2025 - EX-99.1 EX-99.1
• 06.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.15.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]